Fujifilm

Fujifilm Holdings Corporation, (富士フイルム株式会社, Fujifuirumu Kabushiki-kaisha), better known as Fujifilm or simply Fuji, is a Japanese multinational photography and imaging company headquartered in Tokyo.

Fujifilm's principal activities are the development, production, sale and servicing of business document solutions, medical imaging and diagnostics equipment, cosmetics, optical films for flat panel displays, optical devices, photocopiers and printers, digital cameras, color film, color paper, photofinishing equipment, photofinishing chemicals, graphic arts equipment and materials.

History

20th century

Fuji Photo Film Co., Ltd. was established in 1934 with the aim of being the first Japanese producer of photographic films. Over the following 10 years, the company produced photographic films, motion-picture films and X-ray films. In the 1940s, Fuji Photo entered the optical glasses, lenses and equipment markets. After the Second World War, Fuji Photo diversified, penetrating the medical (X-ray diagnosis), printing, electronic imaging and magnetic materials fields. In 1962, Fuji Photo and U.K.-based Rank Xerox Limited (now Xerox Limited) launched Fuji Xerox Co., Ltd. through a joint venture.

Lymphocyte cytosolic protein 2

Lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa), also known as LCP2 or SLP-76, is a gene that encodes a signal-transducing adaptor protein.

Structure

No full structure for SLP-76 has been solved. The PDB file 1H3H depicts the SH3 domain of GRAP2 in complex with an RSTK-containing peptide representing residues 226-235 of SLP-76.

Function

SLP-76 was originally identified as a substrate of the ZAP-70 protein tyrosine kinase following T cell receptor (TCR) ligation in the leukemic T cell line Jurkat. The SLP-76 locus has been localized to human chromosome 5q33 and the gene structure has been partially characterized in mice. The human and murine cDNAs both encode 533 amino acid proteins that are 72% identical and composed of three modular domains. The NH2-terminus contains an acidic region that includes a PEST domain and several tyrosine residues that are phosphorylated following TCR ligation. SLP-76 also contains a central proline-rich domain and a COOH-terminal SH2 domain. A number of additional proteins have been identified that associate with SLP-76 both constitutively and inducibly following receptor ligation, supporting the notion that SLP-76 functions as an adaptor or scaffold protein. Studies using SLP-76-deficient T cell lines or mice have provided strong evidence that SLP-76 plays a positive role in promoting T cell development and activation as well as mast cell and platelet function.

SLP1

The "Sanskrit Library Phonetic Basic encoding scheme" (SLP1) is an ASCII transliteration scheme for the Sanskrit language from and to the Devanagari script.

Differently from other transliteration schemes for Sanskrit, it can represent not only the basic Devanagari letters, but also phonetic segments, phonetic features and punctuation. SLP1 also describes how to encode classical and Vedic Sanskrit.

One of the main advantages of SLP1 is that each Devanagari letter used in Sanskrit maps to exactly one ASCII character, making it possible to create simple conversions between ASCII and Sanskrit. For example, the Harvard-Kyoto transliteration uses the single character "D" to represent "ड" and the combination "Dh" to represent "ढ". SLP1, in contrast, always uses a single character: "q" for "ड" and "Q" for "ढ".

The tables in the following sections are taken from Peter Scharf's May 2008 talk.

History

SLP1 has been formally introduced in the book Linguistic Issues in Encoding Sanskrit by Peter M. Scharf and Malcolm D. Hyman as part of the Sanskrit Library project.

Soulcalibur III

Soulcalibur III (ソウルキャリバーIII, SōruKyaribā Surī) is a fighting game produced by Namco as a sequel to Soulcalibur II and the fourth installment in the Soul series. It was originally released exclusively for the PlayStation 2 in 2005. An improved arcade version, Soulcalibur III: Arcade Edition, was released in 2006.

Gameplay

The game includes new modes such as Tales of Souls, an interactive story-driven mode comparable to Edge Master Mode from Soul Edge; Character Creation, in which players can create custom characters from 13 total occupations, with multiple weapons and fighting styles; and Chronicles of the Sword, a real-time-play mode that allows players to take their created souls through adventures of their own. The game also has the largest character roster — 24 characters playable in Tales of Souls mode and an additional 18 playable in all other modes — and largest battle stage selection in Soul series history.

The Character Creation Mode allows the player to choose from several classes, clothing and armor, and physical features. Most of the classes can use up to five disciplines, three of which are unique, and two of which are "Soul of ..." disciplines: an exact replica of a main story character's moves. The created fighter's personality can be altered, which influences their quotes and their actions during battle. However, the personality is chosen by the equipment the character wears, and not directly by the player.

New START

New START (Strategic Arms Reduction Treaty) (Russian: СНВ-III, SNV-III) is a nuclear arms reduction treaty between the United States of America and the Russian Federation with the formal name of Measures for the Further Reduction and Limitation of Strategic Offensive Arms. It was signed on 8 April 2010 in Prague, and, after ratification, entered into force on 5 February 2011. It is expected to last at least until 2021.

New START replaced the Treaty of Moscow (SORT), which was due to expire in December 2012. In terms of name, it is a follow-up to the START I treaty, which expired in December 2009, the proposed START II treaty, which never entered into force, and the START III treaty, for which negotiations were never concluded.

Under terms of the treaty, the number of strategic nuclear missile launchers will be reduced by half. A new inspection and verification regime will be established, replacing the SORT mechanism. It does not limit the number of operationally inactive stockpiled nuclear warheads that remain in the high thousands in both the Russian and American inventories.

Prince Karl Emich of Leiningen

Prince Karl Emich of Leiningen (born Karl Emich Nikolaus Friedrich Hermann Prinz zu Leiningen; June 12, 1952) is the eldest son of Emich, 7th Prince of Leiningen and his wife Duchess Eilika of Oldenburg, and is an elder brother of Andreas, 8th Prince of Leiningen. He is a claimant to the defunct throne of the Russian Empire, held until 1917 by the Imperial House of Romanov, as a grandson of Grand Duchess Maria Kirillovna (1907-1951), eldest child of Grand Duke Kirill Vladimirovich, who claimed the Russian crown from exile in 1924. He is a great-great-grandson of Emperor Alexander II of Russia and grand nephew of Grand Duke Vladimir Kirillovich of Russia.

In 2013, the Monarchist Party of Russia declared him the primary heir to the Russian throne upon his conversion from Lutheranism to Eastern Orthodox Christianity, and in 2014 announced the formation of the Imperial Throne, wherein Karl Emich had agreed to assume imperial dignity as Emperor Nicholas III.

Marriages and children